|
1
|
Axente L, Sinescu C and Bazacliu G: Heart failure prognostic model. J Med Life. 4:210–225. 2011.PubMed/NCBI
|
|
2
|
Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W and Haass M: Health related quality of life in patients with congestive heart failure: Comparison with other chronic diseases and relation to functional variables. Heart. 87:235–241. 2002.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Clark AL, Johnson M, Fairhurst C, Torgerson D, Cockayne S, Rodgers S, Griffin S, Allgar V, Jones L, Nabb S, et al: Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. Health Technol Assess. 19:1–120. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
McMurray JJ and Pfeffer MA: Heart failure. Lancet. 365:1877–1889. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 10:933–989. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR and Sculpher M: The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective. Heart. 100:1031–1036. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, et al: Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 119:e21–e181. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vildbrad MD, Andersen A, Holmboe S, Ringgaard S, Nielsen JM and Nielsen-Kudsk JE: Acute effects of levosimendan in experimental models of right ventricular hypertrophy and failure. Pulm Circ. 4:511–519. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Andersen S, Schultz JG, Holmboe S, Axelsen JB, Hansen MS, Lyhne MD, Nielsen-Kudsk JE and Andersen A: A Pulmonary Trunk Banding Model of pressure overload induced right ventricular hypertrophy and failure. J Vis Exp: Nov 29, 2018 (Epub ahead of print). doi: 10.3791/58050.
|
|
10
|
Hirata M, Ousaka D, Arai S, Okuyama M, Tarui S, Kobayashi J, Kasahara S and Sano S: Novel model of Pulmonary Artery Banding leading to right heart failure in rats. Biomed Res Int. 2015(753210)2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bae HK, Lee H, Kim KC and Hong YM: The effect of sildenafil on right ventricular remodeling in a rat model of monocrotaline-induced right ventricular failure. Korean J Pediatr. 59:262–270. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mendes-Ferreira P, Maia-Rocha C, Adão R, Mendes MJ, Santos-Ribeiro D, Alves BS, Cerqueira RJ, Castro-Chaves P, Lourenço AP, De Keulenaer GW, et al: Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. Cardiovasc Res. 109:44–54. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nogueira-Ferreira R, Vitorino R, Ferreira R and Henriques-Coelho T: Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 35:8–16. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rain S, Andersen S, Najafi A, Gammelgaard Schultz J, da Silva Goncalves Bos D, Handoko ML, Bogaard HJ, Vonk-Noordegraaf A, Andersen A, van der Velden J, et al: Right ventricular myocardial stiffness in experimental pulmonary arterial hypertension: Relative contribution of fibrosis and myofibril stiffness. Circ Heart Fail. 9(e002636)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Campian ME, Hardziyenka M, Michel MC and Tan HL: How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol. 373:391–400. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF and Bogaard HJ: The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 302:L363–L369. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dickinson MG, Bartelds B, Borgdorff MA and Berger RM: The role of disturbed blood flow in the development of pulmonary arterial hypertension: Lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol. 305:L1–L14. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Naeije R and Dewachter L: Animal models of pulmonary arterial hypertension. Rev Mal Respir. 24:481–496. 2007.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
19
|
Yao J, Li CG, Gong LK, Feng CC, Li CZ, Gao M, Luan Y, Qi XM and Ren J: Hepatic cytochrome P450s play a major role in monocrotaline-induced renal toxicity in mice. Acta Pharmacol Sin. 35:292–300. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Harjola VP, Mebazaa A, Čelutkienė J, Bettex D, Bueno H, Chioncel O, Crespo-Leiro MG, Falk V, Filippatos G, Gibbs S, et al: Contemporary management of acute right ventricular failure: A statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 18:226–241. 2016.PubMed/NCBI View Article : Google Scholar
|
